Prevalence of Vision Loss in North Africa and Middle East in 2020: Magnitude and Temporal Trends.

IF 1.7 4区医学 Q3 OPHTHALMOLOGY

Ophthalmic epidemiology Pub Date : 2025-04-02 DOI:10.1080/09286586.2025.2457629

Vision Loss Expert Group Of The Global Burden Of Disease Study, The Gbd Blindness And Vision Impairment Collaborators

{"title":"Prevalence of Vision Loss in North Africa and Middle East in 2020: Magnitude and Temporal Trends.","authors":"Vision Loss Expert Group Of The Global Burden Of Disease Study, The Gbd Blindness And Vision Impairment Collaborators","doi":"10.1080/09286586.2025.2457629","DOIUrl":null,"url":null,"abstract":"Purpose: The purpose of the current study was to update the prevalence of blindness and visual impairment (VI) in North Africa and the Middle East (NAME) region and to address the current status of its trends in 2020.Methods: We performed a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. We assessed the prevalence of blindness, moderate and severe VI (MSVI), severe VI, moderate VI, mild VI, and presbyopia in NAME region in 2020.Results: In NAME region in 2020, the age-standardised prevalence per 1000, for all ages and sexes, was 0.70 (0.59-0.80) for blindness, 4.31 (3.91-4.72) for MSVI, 0.54 (0.47-0.60) for severe VI, 3.77 (3.38-4.18) for moderate VI, 2.68 (2.42-2.97) for mild VI, and 3.21 (2.29-4.35) for presbyopia. The all-ages and ≥50 year's age-standardised prevalence were higher in females than in males for all categories of vision impairment. In 2020, 3.09 (2.51-3.75) million people were blind, 21.83 (18.97-24.97) million had MSVI, 2.53 (2.11-3.03) million had severe VI, and 19.30 (16.57-22.27) million had moderate VI. Between 2000 and 2020, age-standardised prevalence of blindness and other categories of visual impairment decreased in all ages and among adults over than 50 years.Conclusion: Although the absolute numbers of people with blindness and MSVI have increased between 1990 and 2020 in NAME region, the overall prevalence and the age standardized prevalence in those aged 50+ years have decreased significantly for the same period.","PeriodicalId":19607,"journal":{"name":"Ophthalmic epidemiology","volume":" ","pages":"1-11"},"PeriodicalIF":1.7000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic epidemiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09286586.2025.2457629","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The purpose of the current study was to update the prevalence of blindness and visual impairment (VI) in North Africa and the Middle East (NAME) region and to address the current status of its trends in 2020.

Methods: We performed a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. We assessed the prevalence of blindness, moderate and severe VI (MSVI), severe VI, moderate VI, mild VI, and presbyopia in NAME region in 2020.

Results: In NAME region in 2020, the age-standardised prevalence per 1000, for all ages and sexes, was 0.70 (0.59-0.80) for blindness, 4.31 (3.91-4.72) for MSVI, 0.54 (0.47-0.60) for severe VI, 3.77 (3.38-4.18) for moderate VI, 2.68 (2.42-2.97) for mild VI, and 3.21 (2.29-4.35) for presbyopia. The all-ages and ≥50 year's age-standardised prevalence were higher in females than in males for all categories of vision impairment. In 2020, 3.09 (2.51-3.75) million people were blind, 21.83 (18.97-24.97) million had MSVI, 2.53 (2.11-3.03) million had severe VI, and 19.30 (16.57-22.27) million had moderate VI. Between 2000 and 2020, age-standardised prevalence of blindness and other categories of visual impairment decreased in all ages and among adults over than 50 years.

Conclusion: Although the absolute numbers of people with blindness and MSVI have increased between 1990 and 2020 in NAME region, the overall prevalence and the age standardized prevalence in those aged 50+ years have decreased significantly for the same period.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmic epidemiology 医学-眼科学

CiteScore

3.70

自引率

5.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Ophthalmic Epidemiology is dedicated to the publication of original research into eye and vision health in the fields of epidemiology, public health and the prevention of blindness. Ophthalmic Epidemiology publishes editorials, original research reports, systematic reviews and meta-analysis articles, brief communications and letters to the editor on all subjects related to ophthalmic epidemiology. A broad range of topics is suitable, such as: evaluating the risk of ocular diseases, general and specific study designs, screening program implementation and evaluation, eye health care access, delivery and outcomes, therapeutic efficacy or effectiveness, disease prognosis and quality of life, cost-benefit analysis, biostatistical theory and risk factor analysis. We are looking to expand our engagement with reports of international interest, including those regarding problems affecting developing countries, although reports from all over the world potentially are suitable. Clinical case reports, small case series (not enough for a cohort analysis) articles and animal research reports are not appropriate for this journal.